Ahmad Jingo, MD
Internal Medicine · Decatur, GANPI 1467416602
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,964 of the $9,461 with a category attached, or 73.6%. 41 manufacturers reported payments, led by Eli Lilly at 30.1% of the total. 2025 is the largest year on record at $3,967, 4.9 times the $802 reported in 2019. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 413 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- AstraZeneca$1K
- AbbVie$1K
- GSK$549
- Novo Nordisk$427
- Collegium Pharmaceutical, Inc.$384
- plus $3K from 35 others
Across 15 payments — averaging $57,945 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$853K
- Eli Lilly Export S.A. Puerto Rico Branch$8K
- AstraZeneca$8K
What the payments were for
- Travel & lodging$2,49126%
- Food & beverage$6,96474%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,461 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 189 | $218,375 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 258 | $183,439 |
| FarxigaDapagliflozin Propanediol | 132 | $165,499 |
| MounjaroTirzepatide | 100 | $133,044 |
| LinzessLinaclotide | 107 | $111,361 |
| VraylarCariprazine Hcl | 53 | $77,536 |
| EntrestoSacubitril/Valsartan | 62 | $75,208 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,589 | $68,433 |
| EliquisApixaban | 58 | $59,806 |
| TrulicityDulaglutide | 38 | $45,888 |
| JardianceEmpagliflozin | 38 | $45,802 |
| XifaxanRifaximin | 13 | $42,696 |
| JanumetSitagliptin Phos/Metformin Hcl | 44 | $39,870 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 72 | $38,473 |
| XareltoRivaroxaban | 32 | $36,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $427 | $218,375189 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,240 | $191,379184 claims |
| AbbVieLinzess, Vraylar | $1,046 | $188,897160 claims |
| GSKTrelegy Ellipta | $549 | $183,439258 claims |
| Lilly USA, LLCMounjaro, Trulicity | $334 | $178,932138 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $292 | $84,275110 claims |
| NovartisEntresto | $105 | $75,20862 claims |
| MerckJanumet, Januvia | $20 | $62,24066 claims |
| PfizerEliquis | $176 | $59,80658 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $145 | $42,69613 claims |
| Johnson & JohnsonXarelto | $76 | $36,17632 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $384 | $28,27772 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Decatur
- John WardDecatur$30K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.